Inspire Medical Systems Faces Sell Rating After 2026 Guidance Cut

Key Facts

1Inspire Medical Systems reported Q1 revenue growth of only 1.6%.

2Management slashed 2026 guidance by up to 10%.

3The company faces operational headwinds including competition from GLP-1 drugs and coding challenges with the new Inspire 5 system.

Inspire Medical Systems maintains a 'Sell' rating following a weak Q1 earnings report characterized by a minimal revenue growth of just 1.6%. Management significantly lowered its 2026 financial guidance by up to 10%, triggering concerns over the company's long-term growth trajectory. The downward revision is primarily driven by intensifying competition from GLP-1 weight-loss drugs and operational hurdles regarding the coding of the new Inspire 5 system. Furthermore, the company is shifting its strategy away from aggressive expansion toward supporting existing accounts amid reimbursement headwinds. These structural challenges have prompted analysts to warn of potential institutional de-risking. Consequently, the outlook remains bearish as the firm navigates a tightening competitive landscape in the medical device sector.